Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

Neutral

AI Analysis

Summary

Emerald Clinical Trials announced the appointment of Michael Stibilj as Chief Executive Officer, effective October 1, 2026, to lead the organization's next phase of global growth.

Importance:2/10

Sentiment:

0.00

Management ChangeCEO AppointmentClinical Research Organization

Related Companies

$GBCMD

Read the original article

Published by PR Newswire Biotech on October 1, 2026 3:00 AM

Read Original